Drug Delivery Technology Development in Canada

Wasan, Kishor; Badea, Ildiko

doi:10.3390/books978-3-03928-005-6

dc.contributor.author	Wasan, Kishor	*
dc.contributor.author	Badea, Ildiko	*
dc.date.accessioned	2021-02-11T11:49:02Z
dc.date.available	2021-02-11T11:49:02Z
dc.date.issued	2019	*
dc.date.submitted	2020-01-07 09:21:22	*
dc.identifier	43244	*
dc.identifier.uri	https://directory.doabooks.org/handle/20.500.12854/45503
dc.description.abstract	Canada continues to have a rich history of ground-breaking research in drug delivery within academic institutions, pharmaceutical industry and the biotechnology community.	*
dc.language	English	*
dc.subject	R5-920	*
dc.subject	RM1-950	*
dc.subject.classification	thema EDItEUR::M Medicine and Nursing	en_US
dc.subject.other	encapsulation	*
dc.subject.other	biodistribution	*
dc.subject.other	pharmaceutics	*
dc.subject.other	targeted therapies	*
dc.subject.other	gambogic acid	*
dc.subject.other	GE11 peptide	*
dc.subject.other	formulation and dosage form development	*
dc.subject.other	transient modulation	*
dc.subject.other	ROESY NMR spectroscopy	*
dc.subject.other	bioaccessibility	*
dc.subject.other	polymeric micelle	*
dc.subject.other	pharmacological Inhibitors of HIF-1 and STAT3	*
dc.subject.other	nanoparticles	*
dc.subject.other	Vitamin D	*
dc.subject.other	drug discovery	*
dc.subject.other	EGFR-targeted therapy	*
dc.subject.other	translational research	*
dc.subject.other	clinical trials	*
dc.subject.other	doxorubicin	*
dc.subject.other	dissolution	*
dc.subject.other	drug development	*
dc.subject.other	permeation enhancers	*
dc.subject.other	Canada	*
dc.subject.other	plant	*
dc.subject.other	primary central nervous system lymphomas	*
dc.subject.other	photostabilizers	*
dc.subject.other	head and neck squamous cell carcinoma	*
dc.subject.other	mouse models	*
dc.subject.other	drug delivery systems	*
dc.subject.other	melphalan	*
dc.subject.other	hypoxia-induced chemoresistance	*
dc.subject.other	skin	*
dc.subject.other	virus	*
dc.subject.other	circadian clock	*
dc.subject.other	child friendly formulation	*
dc.subject.other	adenanthin	*
dc.subject.other	co-delivery	*
dc.subject.other	canola oil deodorizer distillate	*
dc.subject.other	Metaplex	*
dc.subject.other	innovation	*
dc.subject.other	controlled drug delivery	*
dc.subject.other	nifedipine	*
dc.subject.other	radiolabeling	*
dc.subject.other	amphotericin B	*
dc.subject.other	biological barriers	*
dc.subject.other	blood-brain barrier (BBB)	*
dc.subject.other	biologicals	*
dc.subject.other	lipid nanoparticles	*
dc.subject.other	oral formulation	*
dc.subject.other	phytosterols	*
dc.subject.other	medical devices	*
dc.subject.other	chronotherapy	*
dc.subject.other	oral	*
dc.subject.other	cationic gemini surfactant	*
dc.subject.other	route of administration	*
dc.subject.other	drug delivery	*
dc.subject.other	intra-arterial chemotherapy	*
dc.subject.other	developing world	*
dc.subject.other	sustained delivery	*
dc.subject.other	water miscible solvents	*
dc.subject.other	combination therapy	*
dc.subject.other	antibodies	*
dc.subject.other	throughput	*
dc.subject.other	magnetic fields	*
dc.subject.other	liposomes	*
dc.subject.other	medulloblastoma	*
dc.subject.other	drug-resistant melanoma	*
dc.subject.other	rosmarinic acid	*
dc.subject.other	topical formulation	*
dc.subject.other	TNO gastrointestinal model	*
dc.subject.other	gastrointestinal simulator	*
dc.subject.other	malignant gliomas	*
dc.subject.other	transdermal drug delivery	*
dc.subject.other	oral delivery	*
dc.subject.other	precision medicine	*
dc.subject.other	3D spheroid	*
dc.subject.other	flavonoids	*
dc.subject.other	staurosporine	*
dc.subject.other	DOX-Vit D	*
dc.subject.other	loading gradients	*
dc.subject.other	bacteriophage	*
dc.subject.other	phospholipid complex	*
dc.subject.other	triggered drug release	*
dc.subject.other	HIF-1	*
dc.subject.other	phage display	*
dc.subject.other	pharmacokinetics	*
dc.subject.other	emulsion	*
dc.subject.other	quercetin	*
dc.subject.other	cisplatin	*
dc.subject.other	parasitic infections	*
dc.subject.other	remote loading	*
dc.subject.other	HAV6 cadherin peptide	*
dc.subject.other	blood-brain barrier	*
dc.subject.other	inclusion complex	*
dc.subject.other	tocopherols	*
dc.subject.other	STAT3	*
dc.subject.other	ultrasound	*
dc.subject.other	liposome	*
dc.subject.other	fungal infections	*
dc.subject.other	magnetic resonance imaging (MRI)	*
dc.subject.other	MG63	*
dc.subject.other	model orange juice	*
dc.subject.other	radiation	*
dc.subject.other	cancer	*
dc.subject.other	mefloquine	*
dc.subject.other	small molecules	*
dc.title	Drug Delivery Technology Development in Canada	*
dc.type	book
oapen.identifier.doi	10.3390/books978-3-03928-005-6	*
oapen.relation.isPublishedBy	46cabcaa-dd94-4bfe-87b4-55023c1b36d0	*
oapen.relation.isbn	9783039280056	*
oapen.relation.isbn	9783039280049	*
oapen.pages	352	*
oapen.edition	1st	*

Fichier(s) constituant ce document

Fichiers	Taille	Format	Vue
Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Imported or submitted locally

Afficher la notice abrégée

Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by-nc-nd/4.0/